AI powered solution for personalised health

人工智能驱动的个性化健康解决方案

• 批准号: 10043653
• 金额: $ 6.37万
• 依托单位: VANN LIMITED
• 依托单位国家: 英国
• 项目类别: Grant for R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10043653
• 关键词: AI; powered; solution; personalised; health

Vann provides a digital platform that offers community support to people living with cancer and beyond, provides them with helpful resources and tools, as well as offers studies and surveys to take part in. Real World Data collected though studies and surveys will contribute to cancer research and drug development.Within the scope of this project, we plan toa) develop an AI powered tool, which will offer personalised information to patients based on their stage of treatment. This will supplement the existing platform and will leverage data that the users share through targeted research studies and surveys. This tool will be included in the premium plan, serving as a direct source of revenue.b) conduct a feasibility study in order to analyse and evaluate the potential for the application of pharmacogenomics in our work. In particular, connecting genomic data with health and lifestyle data of users will enable the tool to focus on personalised medicine for the purposes of cancer prevention and to improve understanding of short-term and long-term side effects as well as the impact of cancer treatments on the quality of life of patients.This grant funding will help to accelerate patient access to Vann's elegant and sophisticated platform and it will also allow earlier commercialisation.

Vann提供了一个数字平台，为癌症患者及其他患者提供社区支持，为他们提供有用的资源和工具，并提供研究和调查。通过研究和调查收集的真实的世界数据将有助于癌症研究和药物开发。在该项目的范围内，我们计划a）开发一种人工智能驱动的工具，该工具将根据患者的治疗阶段为患者提供个性化信息。这将补充现有的平台，并将利用用户通过有针对性的研究和调查分享的数据。这一工具将被纳入保费计划，作为直接的收入来源。B）进行可行性研究，以分析和评估药物基因组学在我们工作中应用的潜力。特别是，将基因组数据与用户的健康和生活方式数据联系起来，将使该工具能够专注于以癌症预防为目的的个性化医疗，并提高对短期和长期癌症的理解。长期副作用以及癌症治疗对患者生活质量的影响。这笔赠款资金将有助于加快患者访问Vann的优雅和复杂的平台，早期商业化。